Image
Image

The First Personalized Rule-In Drug Response Test For RA Therapies

Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues within the joints. There are currently ~2 million1 RA patients in America, with 120,0001 new diagnoses each year.

Exagen Inc. has partnered with Queen Mary University of London to develop novel patented molecular signatures for rheumatoid arthritis biologic therapeutic selection.  The result provides rheumatologists the ability to reliably predict positive patient response prior to the selection of commonly prescribed biological therapeutic agents.

RA patients experience a low response rate to existing therapeutics

Of the $30 Billion2 spent in America each year on RA therapeutics, an estimated $18 Billion is wasted due to low response rates.

Image

Do NOT achieve an
ACR20 response

Image

Do NOT achieve an
ACR50 response

Image

Do NOT achieve an
ACR 70 response

Pitzalis et al. Nature Reviews Rheumatology. 2020
*ACR response rates include all RA therapeutics


Our Unique 'Individual Patient Signature' Helps Guide Treatment

An 'Individual Patient Signature' is based on the following features:

Image

Clinical disease activity indices

Image
Image

Gene expression analysis performed on synovial tissue

Image
Image

Conventional RA lab tests

Source: Ribera et al. Annals of
Rheumatic Diseases. 2019

Image
Do NOT achieve an ACR20 response
Image
Do NOT achieve an ACR50 response
Image
Do NOT achieve an ACR70 response
Source:
Pitzalis et al. Nature Reviews Rheumatology. 2020
*ACR response rates include all RA therapeutics
Image

Existing Patient Journey 3

Once a patient fails to respond, a healthcare provider has 12 drugs to choose from with no current rule-in test to direct their decision.

Image

AVISE RADR Patient Journey

Speed and accuracy in testing has the potential of protecting a patient's joints and is cost effective

AVISE RADR brings personalized precision oncology-style drug response testing to rheumatology

Image
Innovative

First rule-in test for
rheumatoid arthritis therapies

Image
Accelerates Treatment

Shortens time to efficacious treatment
and disease control

Image
Healthcare Benefits

Stops patient cycling
Increases cost savings

Rheumatoid Arthritis Scientific Advisory Board

Grid Team

Stanley Cohen, M.D.

UT Southwestern Medical Center

Stanley Cohen, M.D. is a Clinical Professor in the Department of Internal Medicine
Grid Team

Andrew Concoff, M.D.

United Rheumatology

Andrew Concoff, MD, FACR, CAQSM is the Executive Vice President, Chief Medical Officer at Un
Grid Team

Kevin Deane, MD, PhD

University of Colorado Anschutz

Kevin Deane, MD, PhD is a Professor of Medicine in the Division of Rheumatology at the Unive
Grid Team

Paul J. DeMarco, M.D.

Georgetown University School of Medicine

Paul J. DeMarco, M.D. is a Board-Certified Rheumatologist, a Fellow of the American College
Grid Team

Harris Perlman, PhD

Northwestern University Feinberg School of Medicine

Harris Perlman, PhD is Chief of Rheumatology and the

Grid Team

Eric Ruderman, M.D.

Northwestern University Feinberg School of Medicine

Eric Ruderman, MD is the Associate Chief, Clinical Af

Grid Team

Marina Sirota, PhD

Bakar Computational Health Sciences Institute

Marina Sirota, PhD is an Associate Professor at the Bakar Computational Health Sciences Inst

Want to learn more about AVISE RADR?

Exagen aids patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions.

To learn more about AVISE® RADR complete this form and an Exagen representative will contact you.

  • This field is for validation purposes and should be left unchanged.

Sources:

  1. Myasoedova et al. Arthritis & Rheumatology 2010 .
  2. IQVIA DDD Data; IBM Truven patient claims data; Cowen Therapeutic Categories Outlook Feb 2021
  3. Lewis et al. Cell Reports. 2019